1995~2016年FDA批准药物分析之2型糖尿病治疗药物研发趋势

Analysis of FDA-Approved Drugs from 1995 to 2016:Development Trends in Drug Therapy for Type 2 Diabetes

目的通过对1995~2016年获美国FDA批准的2型糖尿病治疗药物,从药物的作用机制、临床应用等方面进行分析归纳和总结,研究2型糖尿病治疗药物研发的趋势和规律。方法查阅和检索FDA官网、Pubmed数据库、万方、中国知网、百度学术等数据库,收集、统计、分析以及归纳美国1995~2016年批准上市的治疗2型糖尿病的新药。根据药物的作用机制和作用靶点等信息,运用对比分析法对2型糖尿病治疗药物进行分析。结果按照作用靶点来分类,1995~2016年这20年来FDA批准上市的2型糖尿病药物的种类在不断发生变化,研发方向主要是在钠-葡萄糖转运蛋白2抑制剂。结论从整体上看,作用于受体的药物占据了第1位,占据第2位是作用于酶类的药物;由此可见,作用靶点在受体的药物仍旧是2型糖尿病治疗药物研发的重要趋势和研究方向。

Objective To study the trend and law of drug development for the treatment of type 2 diabetes by analyzing and summarizing the mechanism of action and clinical application of the drugs approved by United States FDA during 1995~2016.Methods The official website of FDA,Pubmed database,Wanfang,CNKI,Baidu Academic and other databases were consulted and searched to collect,statistically analyze and summarize the new drugs approved for the treatment of type 2 diabetes in the United States from 1995 to 2016.According to the mechanism and target of action of drugs,comparative analysis was used to analyze the drugs for the treatment of type 2 diabetes.Results According to the classification of targets,the types of type 2 diabetes drugs approved by the FDA for marketing in the past 20 years from 1995~2016 have been constantly changing,and the research and development direction is mainly in sodium-glucose transporter 2 inhibitors.Conclusion Overall,drugs that act on receptors take the first place,followed by drugs that act on enzymes;Therefore,drugs targeting receptors are still an important trend and research direction in the research and development of drugs for the treatment of type 2 diabetes.